Qualigen Therapeutics, Inc. (QLGN)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Net loss | - | -2,646,172 | ||
| Deemed dividend arising from warrant down-round provision | 1,586 | - | ||
| Loss on disposal of discontinued operations, net of tax | - | - | ||
| Gain (loss) from discontinued operations | - | - | ||
| (benefit from) provision for income taxes | - | 35 | ||
| Research and development | 17,815 | 33,167 | ||
| General and administrative | 1,394,932 | 2,494,532 | ||
| Credit loss expense - short-term note receivable | 271,000 | 197,000 | ||
| Total expenses | 1,683,747 | 2,724,699 | ||
| Loss from operations | -1,683,747 | -2,724,699 | ||
| Interest income | 142,477 | 112,953 | ||
| Interest expense | 106,052 | 73,615 | ||
| Gain on change in fair value of convertible debt | 37,874 | - | ||
| Gain on change in fair value of derivative liabilities | - | - | ||
| Loss on monthly redemptions of convertible debt into common stock | - | - | ||
| Loss on issuance of convertible debt | 91,943 | - | ||
| Gain on change in fair value of warrant liabilities | 15,974 | 39,224 | ||
| Gain on voluntary conversion of convertible debt into common stock | - | - | ||
| Total other expense (income), net | -1,670 | 78,562 | ||
| Loss before (benefit from) provision for income taxes | -1,685,417 | -2,646,137 | ||
| Net loss from continuing operations | -1,685,417 | -2,646,172 | ||
| Net loss | -1,685,417 | - | ||
| Net loss attributable to qualigen therapeutics, inc | -1,687,003 | -2,646,172 | ||
| Total net loss per common share, basic | -1 | -1.82 | ||
| Total net loss per common share, diluted | -1 | -1.82 | ||
| Weighted-average number of shares outstanding, basic | 1,683,881 | 1,456,714 | ||
| Weighted-average number of shares outstanding, diluted | 1,683,881 | 1,456,714 | ||